Journal Home
Search for

Volume 145, Issue 6, Pages 316-322 (June 2005)


View previous. 11 of 17 View next.

Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells

Nobuhiko Higashia, Motoyuki Kohjimaa, Marie Fukushimaa, Satoshi Ohtaa, Kazuhiro Kotoha, Munechika Enjojia, Naoya Kobayashib, Makoto NakamutaaCorresponding Author Informationemail address

Received 14 January 2005; received in revised form 11 March 2005; accepted 22 March 2005.

Epigallocatechin-3-gallate (EGCG), a major constituent of the polyphenoids in green tea, has been reported to possess a wide range of biologic activities, including antifibrogenesis. Activated hepatic stellate cells (HSCs) are central to hepatic fibrosis, and Rho (a small GTPase)-signaling pathways have been implicated in the activation and proliferation of HSCs. In this study, we investigated the effect of EGCG on Rho-signaling pathways in activated human HSC-derived TWNT-4 cells. EGCG inhibited stress-fiber formation, an indicator of Rho activation, and changed the distribution of α-smooth-muscle actin. These inhibitory effects of EGCG were restored by overexpression of constitutively active Rho. A pull-down assay revealed that activated Rho (GTP-bound state) was strongly inhibited by ECGC and accompanied by suppressed phosphorylation of focal adhesion kinase, which is a regulator of Rho-signaling pathways. 5-Bromo-2′-deoxy-uridine incorporation demonstrated that ECGC (100 μmol/L suppressed cell growth by 80%, and terminal deoxynucleotidyl transferase viotin-deoxyruidine triphosphate nick end-labeling revealed that EGCG (100 μmol/L) caused apoptosis in half of the total cells. EGCG also strongly inhibited lysophoaphatidic acid (an activator of Rho) and induced phosphorylation of mitogen-activated protein kinases (Erk1/2, c-jun kinase, and p38). These findings demonstrate that EGCG regulates the structure and growth of HSCs by way of Rho-signaling pathways and suggest that EGCG has therapeutic potential in the setting of liver fibrosis.

a Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

b Department of Gastroenterological Surgery, Transplantation, and Surgical Oncology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan

Corresponding Author InformationReprint requests: Dr Makoto Nakamuta, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-5282, Japan

PII: S0022-2143(05)00135-6

doi:10.1016/j.lab.2005.03.017


View previous. 11 of 17 View next.